Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist

Diuretic effects of cannabinoid agonists in mice

(2013) Girish R. Chopda et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

(2012) F J Meye et al.   MOLECULAR PSYCHIATRY

Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats

(2011) Torbjörn U. C. Järbe et al.   PSYCHOPHARMACOLOGY

AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice

(2011) Torbjörn U. C. Järbe et al.   PSYCHOPHARMACOLOGY

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel 1′,1′-Chain Substituted Hexahydrocannabinols: 9β-Hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a Highly Potent Cannabinoid Receptor 1 (CB1) Agonist

(2010) Spyros P. Nikas et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze

(2010) Peng Huang et al.   NEUROSCIENCE LETTERS

Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice

(2009) Peng Huang et al.   NEUROSCIENCE LETTERS